Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.
The Danish drugmaker said Monday that it’s dropping a
lawsuit
that claims Hims infringed on a key patent for its Wegovy products, and Hims agreed to no longer advertise compounded GLP-1 products. Hims also said it will offer brand-name Wegovy injections and pills on its website at cash prices, as it does with other telehealth companies it has partnered with.
It’s not clear how much the deal will affect the volume of compounded products prescribed through Hims. The telehealth company said it will continue to offer compounded GLP-1s “if a provider determines that a compounded product is clinically necessary.” Novo said it reserves the right to refile its lawsuit in the future.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/09/novo-nordisk-wegovy-hims-hers-deal/)
